Table 1.

Demographic and clinical features of the serum samples

Sample type	Stage/subtype	Number of samples	Male/female ratio	Age range (years)
Gastric cancer	I	13
	II	6
	III	25
	IV	5
	Unknown	33
Total		82	26:15	28–89
Intestinal cancer	I	9
	II	30
	III	64
	IV	2
	Unknown	8
Total		113	68:45	26–89
Benign diseases	Gastric diseasea	30
	Intestinal diseaseb	42
	Gastrointestinal diseasec	2
Total		74	1:1	31–85
Other cancersd		64	31:33	26–76
Interfering samplese		122	31:30	21–82
Healthy people		133	68:65	18–90
Total		588	159:135	18–90

Notes:

^aGastric disease includes benign gastric tumor, gastric ulcer, gastric polyps, gastritis, reflux esophagitis, and so on.

^bIntestinal disease includes benign colonic neoplasm, colonic polyps, ulcerative colitis, duodenal ulcer bleeding, and so on.

^cGastrointestinal disease samples were collected from two patients diagnosed with colon benign tumor and chronic atrophic gastritis, and colon benign tumor, gastric polyps, and chronic atrophic gastritis, respectively.

^dOther cancers include breast cancer, lung cancer, liver cancer, ovarian cancer, and so on.

^eInterfering samples include serum samples from patients diagnosed with RF positivity, ANA positivity, hyperlipidemia, jaundice, hemolysis, acute suppurative tonsillitis, acute alcoholic pancreatitis, acute pancreatitis, and acute epiglottitis. The figures in bold are highlighted because they are the results of a total calculation for each sample type.

Abbreviations: ANA, antinuclear antibody; RF, rheumatoid factor.